Results 161 to 170 of about 18,827 (200)

In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia-Telangiectasia. [PDF]

Chem Biol Drug Des
Romano A, Buccheri R, Zagni C, Rescifina A.   +3 more
europepmc   +1 more source

Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer. [PDF]

Cancer Med
Chen H, Wu S, Shan Y, Guo X, Lu W, Chen Y, Zhou Y.   +6 more
europepmc   +1 more source

HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma. [PDF]

J Exp Clin Cancer Res
Cheung AHK, Wong KY, Li GY, Xie F, Wu Q, Yuen TTH, Hui PL, Huang P, Liu X, Chen B, Ji F, Dong Y, Cheng AS, Ng CSH, Zhang X, Wong CC, Yu J, Kang W, To KF.   +18 more
europepmc   +1 more source

Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer. [PDF]

Sci Rep
Yu M, Yamashita M, Takada M, Takabatake D, Takahashi M, Kochi M, Uno M, Kondo M, Nagashima T, Fujimoto H, Sakakibara J, Teranaka R, Aogi K, Otsuka M.   +13 more
europepmc   +1 more source

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review. [PDF]

Cancer Chemother Pharmacol
João RB, Soares LR, Ragazzo PC, Freitas-Junior R.   +3 more
europepmc   +1 more source

Development of acute myeloid leukemia (AML) in two breast cancer patients undergoing treatment with long-term palbociclib: a dual case report. [PDF]

Transl Breast Cancer Res
Abdelsalam M, Salem M, Samad NA, Manuel E, Rasul M, Dixon J, Ross L, Chute IC, Wallace M.   +8 more
europepmc   +1 more source

Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India. [PDF]

PLoS One
Mukherjee A, Goyal P, Tripathi R, Goyal S, Batra U, Talwar V, Goel V, Jain A, Saha S, Bothra S, Agrawal C, Chugh S, Doval DC.   +12 more
europepmc   +1 more source

CDK4/6 inhibition induces a senescence-associated secretory phenotype via delayed NF-κB activation. [PDF]

Life Sci Alliance
Yeung JL, Rendleman J, Anderson Westcott L, Ou A, Pressler M, Pagane N, Duba I, Hosuru R, Tumenbayar BI, Risca VI.   +9 more
europepmc   +1 more source

Targeting the LIPH-CD36 axis potentiates CDK4/6 inhibition in ER+ breast cancer

Morandi A, Lorito N, Romano E, Smiriglia A, Bacci M, Bonechi F, González-Fernández M, Pagliantini E, Tani G, Comito G, Simões B, Clarke R, El-botty R, Sourd L, Meattini I, Visani L, Bianchi S, Livi L, Marangoni E, Rottenberg S, Francica P.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Palbociclib

Reactions Weekly, 2021
  +10 more sources